… adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first
… After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were …

… was first recognised during the 1980 influenza A epidemic [12]. However, resistance to
both drugs in seasonal influenza A subtypes was rare (1–2% frequency) until after 2000 when …

… antiviral drugs identified by the MT-DTI model should be considered, when establishing
effective treatment … an FDA-approved drug, but regarded as a promising antiviral drug for SARS-…

… drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and
specific drugs … outcomes were observed after receiving antiviral treatment with oseltamivir [65]. …

… , a key antiviral drug approved for the treatment of Hepatitis C [Citation… antiviral initially
developed to combat Ebola virus and eventually approved under emergency use for the treatment …

… by year. The peptide-based antiviral therapeutics have been approved for the Human … of
target for the designing of effective and safe antiviral drugs without harming the host cell, is an …

… approved by the FDA to treat SARS-CoV-2 infection, no oral antiviral is available for outpatient
treatment. … , therefore, may lead to an effective antiviral treatment. A phase 2 clinical trial (…

… AZ is not approved for antiviral therapy but has been studied in vitro and in clinical trials for
… This review was undertaken to assess key AZ published data on in vitro antiviral activity and …

… Also, its low EC 50 and CC 50 achievable with oral dosing, and synergistic properties
when combined with other antiviral medications (such as nelfinavir and mefloquine), further …

… novel anti-SARS-CoV-2 developments and currently approved diagnostic options around
the globe. It also tracks the development of therapeutic/antiviral drugs and vaccines. …